About this episode
Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts.
Further Listening:
Trillion Dollar Shot
Why WeightWatchers Wants in on Drugs Like Ozempic
Sign up for WSJ’s free What’s News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Get every episode summarized
Each time The Journal. publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Journal.
The MAHA Shake-Up at Steak ‘n Shake
The Journal.
Sep 11, 202619:58completed
What Happened to the Affordable Car?
The Journal.
Sep 10, 202619:09completed
A Data Center Offered $26 Million for Her Land. She Said No.
The Journal.
Sep 9, 202629:22completed
AI Companies Are Buying and Destroying Used Books
The Journal.
Sep 8, 202620:43completed